How will outsourcing change in the future? Find out from our experts in this comparative interview with representatives from pharma and CROs.
The future of individualized medicine: intensified decentralized biotherapeutic production in combination with state-of-the-art diagnostics of the next generation
In this editorial the future of individualized medicine is reviewed, focusing on the decentralization of biotherapeutic production in combination with state-of-the-art diagnostics of the next generation.
In part 2 of this 3-part panel discussion our panelists discuss the exciting topic of regulations as they consider the ICH M10 guidance and where they think the field might be going in the future.
In late 2017 Bioanalysis and Bioanalysis Zone organized a panel discussion comprising of experts from leading CROs and pharmaceutical companies to converse about the latest topics in bioanalysis.
In this series of three panel discussions, key opinion leaders from both industries returned to partake in an open dialogue talking through the latest challenges the industry is facing and what changes they would like to see happen in the coming future.
In part 1 of this 3-part panel discussion filmed in Barcelona our panel of experts discuss the issue of outsourcing and what priorities need considering when making a purchasing decision.
In the final part of this 3-part panel discussion, our experts talk through the recent changes in the type of molecules and technologies the field are working with and what new technologies need to emerge to overcome current problems.
From novel analytical instrumentation to the recent developments in the bioanalysis of biopharmaceuticals and biomarkers, as the New Year starts we’re looking back on the bioanalytical highlights from 2017.
Business of bionanalysis: The impact of mergers, acquisitions, and organic growth on bioanalytical sciences
In this final video the Business of bioanalysis panelists discuss the impact of mergers, acquisitions, and organic growth on bioanalytical sciences. The scientific community in which we work goes beyond affiliation, movement of bioanalytical scientists and talent between CRO, pharmaceutical and instrument vendors. The business is robust, while management of corporate culture is critical.
In part 2 of the Business of Bioanalysis panel discussion 2017 our panelists discuss managing the pipeline of bioanalytical talent and staff, including recruiting, training and retaining key analytical experts. Universities are not the singular source generating talent in bioanalysis skill sets. Beyond compensation, continuous education, cross-training, job rotations, and customized recognition models, within the laboratory, are critical to enticing and retaining ‘the best’ in our CRO and pharmaceutical organizations.
In part 1 of this 3-part video filmed in Los Angeles (CA, USA) our panel of experts discuss investing in emerging bioanalytical technologies – when is too soon and when is too late? Acquisition of new tools to address unmet analytical needs requires practical considerations, such as platform reliability, scalability from discovery to the regulated environment and total cost of ownership.